20 June 2016
Maxim Gorbachev, a partner and portfolio manager at RusnanoMedInvest (RMI) speaks to Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio about Russia’s and Eastern Europe’s largest venture capital company, specializing in innovative developments in the field of pharmaceuticals and biotechnology.
22 June 2015
June 25, 2015, Vedomosti newspaper office will host a FocusForum Conference in Moscow with a leading participation of Leonid Melamed, the Chairman of Team Drive, member of the Board of Directors of NovaMedica, RMI Partners and Doctor Ryadom. The conference’s goal is to gather experts and share ideas and valuable experience in the time of business challenges. In his video interview to Vedomosti, Leonid explained his vision of the company management tasks in the period of uncertainty.
16 October 2014
As part of the Panel Discussion “Optimal Strategies and Exit Models for Venture Investors” held during 3rd Moscow International Forum for Innovative Development “Open Innovations” Evgeny Zaytsev shared his experience of various exit models from venture investments in biotech.
17 November 2017
To ensure the quality and safety of drugs, biologics, and medical products more efficiently and effectively, FDA is making significant changes in its plant inspection program, including more attention to imports and to foreign producers of drugs for American consumers. An aim is to target manufacturing oversight to more high-risk operations and free up resources for greater scrutiny of foreign facilities in the process.
16 November 2017
The European Medicines Agency (EMA) and the European Network for Health Technology Assessment (EUnetHTA) have published a joint work plan outlining key areas of collaboration for the next three years.
16 November 2017
U.S. regulators have approved the first digital pill with an embedded sensor to track if patients are taking their medication properly, marking a significant step forward in the convergence of healthcare and technology.
15 November 2017
The gene editing system CRISPR-Cas9 has generated excitement for its potential use in eliminating disease-causing irregularities in DNA. But most CRISPR systems rely on viruses to carry Cas9 components into cells, where they then go to work cutting DNA.